Home  »  Company  »  Celestial Biolabs Lt  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Celestial Biolabs Ltd.

Mar 31, 2016

Notes to Accounts:

1. Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India the company''s primary business segment is Formulations. During the period your company has achieved a turnover of Rs 3285.54 lacs for Formulations & Feed Supplement.

2 Investment in Total Health Kare International Private Limited subsidiary of Celestial Biolabs Ltd of

Rs. 30.10 Lakhs

4) Paise have been rounded off to the nearest Rupee.

5) On applicability of revised Schedule II from current year, the Company has reclassified previous year figures to conform to this year''s classification. The adoption of revised Schedule II does not impact recognition and measurement principles followed for preparation of the financial statements. However, it significantly impacts presentation and disclosures made in the financial statements, particularly presentation of Balance Sheet.

6).Balance in respect of creditors, Various Advances, Sundry Debtors are subject to confirmation from the respective parties.

7).As the company has not in the possession of information regarding dues to the Micro, Small and Medium Enterprises, the same has not been furnished herewith.

8). Additional Information required under Part II of Schedule V to the Companies Act 2013.

a) Capacities and Production

Product Unit Installed capacity / Actual Production Not Applicable

Licensed Capacity Not Applicable


Mar 31, 2015

1. Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India the company's primary business segment is formulations. During the period your company has achieved a turnover of Rs 2745.07 lacs for formulations.

2. Contingent Liabilities : Nil

3. Paise have been rounded off to the nearest Rupee.

4. On applicability of revised Schedule VI from current year, the Company has reclassified previous year figures to conform to this year's classification. The adoption of revised Schedule VI does not impact recognition and measurement principles followed for preparation of the financial statements. However, it significantly impacts presentation and disclosures made in the financial statements, particularly presentation of Balance Sheet.

5. Balance in respect of creditors, Various Advances, Sundry Debtors are subject to confirmation from the respective parties.

6. As the company has not in the possession of information regarding dues to the Micro, Small and Medium Enterprises, the same has not been furnished herewith.


Mar 31, 2014

1. Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India the company''s primary business segment is formulations. During the period your company has achieved a turnover of Rs 2350.34 lacs for formulations.

2. Related Party disclosures:

SL No Name of Related Party Name of the Transaction Amount

1 Dr. A.N. Singh Remuneration 12.00

2 Padma Singh Sitting Fee 0.10

3 Amit Kumar Singh remuneration 6.00

3. Auditors'' Remuneration:

2013-2014 2012-2013 Rs. Rs.

Audit Fee 3,00,000 3,00,000



4. Treatment of Contingent Liabilities : Liabilities, Which may or may not arise and not crystallized as at the year - end, have been taken as contingent liability. Claims against the company not knowledge as debt in respect of Sales tax and Income Tax Rs. 1.25 crore and Rs.299.06 Lacs respectively

5. Paise have been rounded off to the nearest Rupee.

6. On applicability of revised Schedule VI from current year, the Company has reclassified previous year figures to conform to this year''s classification. The adoption of revised Schedule VI does not impact recognition and measurement principles followed for preparation of the financial statements. However, it significantly impacts presentation and disclosures made in the financial statements, particularly presentation of Balance Sheet.

7.Balance in respect of creditors, Various Advances, Sundry Debtors are subject to confirmation from the respective parties.

8.As the company has not in the possession of information regarding dues to the Micro, Small and Medium Enterprises, the same has not been furnished herewith.

9). Additional Information required under Part II of Schedule VI to the Companies Act 1956. a) Capacities and Production Product Unit Installed capacity / Actual Production Not Applicable Licensed Capacity Not Applicable

10. TECHNOLOGY ABSORPTION: A. Research & Development (R & D)

1 Specific area in which R & D carried out by the company

Isolating the compound from Herbs to identify the active ingredient for diabetes, Obesity & HIV virus.

2 Benefits derived as a result of the above R & D

Lead have been identified and the further process is in progress.

3 Future plan of action

We will continue to work on clinical trial of Bio drug Molecules already in pipe line and isolating the compounds for our target decease.

4 Expenditure on R & D: (Rs. In Lakhs) 2013-14 2012-13

a. Capital 250.00 350.41

b. Recurring 105.64 118.68

c. Total 355.64 469.09

d. Total R & D expenditure as a 15.13% 22.17% percentage of total turnover

Procedure and Instructions for E-Voting are as follows:

i) Open your web browser during the voting period and navigate to ''https://evoting.karvy.com''

ii) Enter the login credentials (i.e., user-id & password) mentioned on the Postal Ballot Form. Your folio/DP Client ID will be your User-ID.

User-ID

For Members holding shares in Demat Form:-

a) For NSDL :- 8 Character DP ID followed by 8 Digits Client ID

b) For CDSL :- 16 digits beneficiary ID

For Members holding shares in Physical Form:-

- Event no. followed by Folio Number registered with the company

Password

Your Unique password is printed on the Postal Ballot Form / via email forwarded through the electronic notice

Captcha

Enter the Verification code i.e., please enter the alphabets and numbers in the exact way as they are displayed for security reasons.

iii) Please contact our toll free No. 1-800-34-54-001 for any further clarifications.

iv) Members can cast their vote online from Monday 10th November, 2014 @ 10:00 AM to Wednesday 12th November, 2014 @ 6:00 PM

v) After entering these details appropriately, click on "LOGIN".

vi) Members holding shares in Demat/Physical form will now reach Password Change menu wherein they are required to mandatorily change their login password in the new password field. The new password has to be minimum eight characters consisting of atleast one upper case (A-Z).one lower case (a-z), one numeric value (0-9) and a special character. Kindly note that this password can be used by the Demat holders for voting for resolution of any other Company on which they are eligible to vote, provided that Company opts for e-voting through Karvy Computershare Private Limited e-Voting platform. System will prompt you to change your password and update any contact details like mobile #, email ID etc on 1st login. You may also enter the Secret Question and answer of your choice to retrieve your password in case you forget it. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

vii) You need to login again with the new credentials.

viii) On successful login, system will prompt to select the ''Event'' i.e., ''Company Name''.

ix) If you are holding shares in Demat form and had logged on to "https://evoting.karvy.com" and casted your vote earlier for any company, then your existing login id and password are to be used.

x) On the voting page, you will see Resolution Description and against the same the option ''FOR/AGAINST/ABSTAIN'' for voting Enter the number of shares (which represents number of votes) under ''FOR/AGAINST/ABSTAIN'' or alternatively you may partially enter any number in ''FOR and partially in ''AGAINST'', but the total number in ''FOR/AGAINST'' taken together should not exceed your total shareholding. If the shareholder do not wants to cast, select''ABSTAIN''

xi) After selecting the resolution you have decided to vote on, click on "SUBMIT''.A confirmation box will be displayed .If you wish to confirm your vote, click on "OK", else to change your vote, click on " CANCEL "and accordingly modify your vote.

xii) Once you ''CONFIRM'' your vote on the resolution, you will not be allowed to modify your vote.

xiii) Corporate/Institutional Members (corporate /Fls/Flls/Trust/Mutual Funds/Banks, etc) are required to send scan (PDF format) of the relevant Board resolution to the Scrutinizer through e-mail to cs@celestialbiolabs.com with copy to evoting@karvy.com.The file scanned image of the Board Resolution should be in the naming format "Corporate Name_ Event no.". Please follow all steps from Sl. No. (i) to Sl. No. (xiii) above, to cast vote.


Mar 31, 2013

1 Related Party Disclosures

The Company had no transactions with related parties as defined in Accounting Standard - 18 issued by the Institute of Chartered Accountants of India.

2 Treatment of Contingent Liabilities: Liabilities, which may or may not arise and not crystallized as at the year- end, have been taken as contingent liability. Claims against the Company not acknow- ledged as Debt in respect of Sales Tax and Income Tax Rs.390.48 Lacs and Rs 299.06 Lacs respectively.

3 CIF Value of Imports NIL NIL

4 Expenditure in Foreign Currency NIL Nil

(on account of Travelling & Professional and Consultancy)

5 Earnings in Foreign Exchange - FOB value of Exports NIL NIL

6 The company operates predominantly only in one Business Segment viz: Herbal, Allopathic etc Products. The sales of the company is mostly in India and there are no reportable geographical segments.

7 The Balances of Loans & Advances, Sundry Debtors and Sundry Creditors are subject to confirmation.

8 The Revised Schedule VI has become effective from 1 April 2012 for the preparation of financial statements. Previous year figures have been regrouped / reclassified wherever necessary to correspond with the current year''s classification / disclosure.

9. Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India the company''s primary business segment is formulations. During the period your company has achieved a turnover of Rs 2115.54 lakh for formulations.

10) Paise have been rounded off to the nearest Rupee.

11) On applicability of revised Schedule VI from current year, the Company has reclassified previous year figures to conform to this year''s classification. The adoption of revised Schedule VI does not impact recognition and measurement principles followed for preparation of the financial statements. However, it significantly impacts presentation and disclosures made in the financial statements, particularly presentation of Balance Sheet.

12). Balance in respect of creditors, Various Advances, Sundry Debtors are subject to confirmation from the respective parties.

13). As the company has not in the possession of information regarding dues to the Micro, Small and Medium Enterprises, the same has not been furnished herewith.


Mar 31, 2012

1. Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India the company's primary business segment is formulations. During the period your company has achieved a turnover of Rs 1324.35 lakh for formulations and Rs 734.53 lakh for Bio IT.

2.Managerial Remuneration under Section 198 of the Companies Act, 1956 paid or payable to the Directors:

3) Paise have been rounded off to the nearest Rupee.

4) On applicability of revised Schedule VI from current year, the Company has reclassified previous year figures to conform to this year's classification. The adoption of revised Schedule VI does not impact recognition and measurement principles followed for preparation of the financial statements. However, it significantly impacts presentation and disclosures made in the financial statements, particularly presentation of Balance Sheet.

5).Balance in respect of creditors, Various Advances, Sundry Debtors are subject to confirmation from the respective parties.

6).As the company has not in the possession of information regarding dues to the Micro, Small and Medium Enterprises, the same has not been furnished herewith.


Mar 31, 2011

1.1 Contingent Liabilities not provided – Nil

1.2 Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India, the company's primary business segment is formulations. During the period your company has achieved a turn over of Rs.1760.31 lakh for formulations and Rs.762.01 lakh for Bio/IT.

1.3 Deferred Tax

The deferred tax asset as at 31st March 2011 is . 16, 01,592.00


Mar 31, 2010

1.1 Contingent Liabilities not provided -Nil

1.2 Segment Reporting:

Based on the guiding principles given in Accounting Standard on Segment Reporting (AS -17) issued by the Institute of Chartered Accountants of India, the companys primary business segment is formulations. During the period your company has achieved a turn over of Rs.1447.23 lakh for formulations and Rs.705.99 lakh for Bio-IT.

1.3 Deferred fax

The deferred tax asset as at 31st March 2010 is Rs. 6,87,866.00

1.4 Additional information required under Part II of Schedule VI to the Companies Act, 1956

1. Capacities and & Production

Product Unit Installed capacity/Actual production Not Applicable

Licensed Capacity Not Applicable

Find IFSC